RESUMEN

Asthma is among the most common chronic disorders of airways, which affects both children and adults. Asthma being a common disease among different segments of population, it has a high mortality rate and, in the absence of appropriate care, affects the quality of life and leads to economics losses. In a view of continuing growth in the incidence of asthma, it is important to find relevant biological targets for developing new approaches to astma therapy. Recent advances in molecular immunology, genetics, and bioinformatics allowed genes involved in the pathogenesis of asthma to be identified, which provided prerequisites for the development of new types of drugs that can regulate the activity of pathogenically significant genes. To date, a number of technologies for sequence-specific gene regulation (ASO, ribozymes, DNAzymes, EGS, DNA-decoys, U 1-adapters) are available, but RNA interference is the most promising approach in both terms of efficacy and financial cost. This review focuses on the generalization and analysis of experimental data regarding the use of RNA interference technology for the treatment of astma.

Asunto(s)

Asma/terapia , Factor de Transcripción GATA3/antagonistas & inhibidores , Terapia Genética/métodos , Interleucina-13/antagonistas & inhibidores , Interleucina-4/antagonistas & inhibidores , Interferencia de ARN , Adulto , Aptámeros de Nucleótidos/genética , Aptámeros de Nucleótidos/metabolismo , Aptámeros de Nucleótidos/uso terapéutico , Asma/genética , Asma/inmunología , Asma/patología , Niño , Enfermedad Crónica , ADN Catalítico/genética , ADN Catalítico/metabolismo , ADN Catalítico/uso terapéutico , Factor de Transcripción GATA3/genética , Factor de Transcripción GATA3/inmunología , Expresión Génica , Predisposición Genética a la Enfermedad , Humanos , Interleucina-13/genética , Interleucina-13/inmunología , Interleucina-4/genética , Interleucina-4/inmunología , Oligonucleótidos Antisentido/genética , Oligonucleótidos Antisentido/metabolismo , Oligonucleótidos Antisentido/uso terapéutico , Calidad de Vida , ARN Catalítico/genética , ARN Catalítico/metabolismo , ARN Catalítico/uso terapéutico